Conditioning regimens in groups of patients receiving transplants from MUDs and MMRDs
| Donors . | 1 alkylator (Treo/Flu)*,† . | 2 alkylators (Treo/Flu + Mel or Thio) . | 2 alkylators (Treo/ Flu + Cy) . | 2 alkylators + G-CSF/plerixafor . | ATGAM . | Thymoglobulin . | Alemtuzumab . | No serotherapy . | Rituximab . |
|---|---|---|---|---|---|---|---|---|---|
| MUD, n = 75 | 21 | 44 | 2 | 8 | 8 | 62 | 3 | 2 | 56 |
| MMRD, n = 23 | 4 | 8 | 2 | 9 | 2 | 21 | 0 | 0 | 20 |
| n | 25 | 52 | 4 | 17 | 10 | 83 | 3 | 2 | 76 |
| Donors . | 1 alkylator (Treo/Flu)*,† . | 2 alkylators (Treo/Flu + Mel or Thio) . | 2 alkylators (Treo/ Flu + Cy) . | 2 alkylators + G-CSF/plerixafor . | ATGAM . | Thymoglobulin . | Alemtuzumab . | No serotherapy . | Rituximab . |
|---|---|---|---|---|---|---|---|---|---|
| MUD, n = 75 | 21 | 44 | 2 | 8 | 8 | 62 | 3 | 2 | 56 |
| MMRD, n = 23 | 4 | 8 | 2 | 9 | 2 | 21 | 0 | 0 | 20 |
| n | 25 | 52 | 4 | 17 | 10 | 83 | 3 | 2 | 76 |
1 alkylator: June 2012 to November 2014; 2 alkylators: from November 2014; 2 alkylators with G-CSF/plerixafor: from May 2016.
Total doses: Flu, fludarabine 150 mg/m2; Treo, treosulfan 42 g/m2 (36 g/m2 in patients younger than 1 year of age); Mel, melphalan 140 mg/m2; Thio, thiotepa 10 mg/kg; Cy, cyclophosphamide 40 to 120 mg/kg; G-CSF, 10 μg/kg/d for 5 days, plerixafor 240 μg/kg/d for 3 days; ATGAM (Pfizer) 90 mg/kg, thymoglobulin (Genzyme Europe B.V.) 5 mg/kg, alemtuzumab 1 mg/kg, rituximab 100-200 mg/m2 on day −1.